Abstract: A highly stable cannabinoid nanoparticle carrier composition for administration to a human made by incorporating non-ionic surfactants with cannabinoid oils and lipids, sonicating for a predetermined period of time at a predetermined amplification with an ultrasonic liquid processor until completely integrated; combining the mixture with a carrier fluid that includes ascorbic acid and distilled water; and further sonicating the mixture using an ultrasonic liquid processor at predetermined amplitude for a predetermined period of time at a controlled temperature, and thereby to create a CBD nanoemulsion. The composition is tailored using non-ionic surfactants to adsorb to the surface of the cannabinoid oil particles to advantageously affect electrokinetics and surface forces at the interface of the bioactive cannabinoid particles and the suspending liquid are controlled by tailoring the suspending liquid to maximize the zeta potential.

Abstract: A method of producing a cannabinoid nanoparticle carrier composition for administration to a human and thereafter producing a consumable food product including the cannabinoid nanoparticle emulsification. The cannabinoid nanoparticle carrier composition is combined with a particulate food product, herb or spice, sugar, salt, or particulate preservative, mixed into a slurry or suspension, dried, and then ground to a size suitable for human consumption.

Abstract: A highly stable cannabinoid nanoparticle carrier composition for administration to a human made by incorporating non-ionic surfactants with cannabinoid oils and lipids, sonicating for a predetermined period of time at a predetermined amplification with an ultrasonic liquid processor until completely integrated; combining the mixture with a carrier fluid that includes ascorbic acid and distilled water; and further sonicating the mixture using an ultrasonic liquid processor at predetermined amplitude for a predetermined period of time at a controlled temperature, and thereby to create a CBD nanoemulsion. The composition is tailored using non-ionic surfactants to adsorb to the surface of the cannabinoid oil particles to advantageously affect electrokinetics and surface forces at the interface of the bioactive cannabinoid particles and the suspending liquid are controlled by tailoring the suspending liquid to maximize the zeta potential.

Abstract: A method of producing a cannabinoid nanoparticle carrier composition for administration to a human, including the steps of incorporating non-ionic surfactants with cannabinoid oils and lipids; inducing sonication for a predetermined period of time at a predetermined amplification with a ultrasonic liquid processor until completely integrated; dissolving ascorbic acid into a carrier fluid; combining in sequence the non-ionic surfactants, lipids, and cannabinoids with a carrier fluid consisting of distilled water and ascorbic acid; sonicating using an ultrasonic liquid processor at predetermined amplitude for a predetermined period of time at a controlled temperature.

Abstract: A method of producing a cannabinoid nanoparticle carrier composition for administration to a human and thereafter producing a consumable food product including the cannabinoid nanoparticle emulsification.

Abstract: A method of producing a cannabinoid nanoparticle carrier composition for administration to a human, including the steps of incorporating non-ionic surfactants with cannabinoid oils and lipids; inducing sonication for a predetermined period of time at a predetermined amplification with a ultrasonic liquid processor until completely integrated; dissolving ascorbic acid into a carrier fluid; combining in sequence the non-ionic surfactants, lipids, and cannabinoids with a carrier fluid consisting of distilled water and ascorbic acid; sonicating using an ultrasonic liquid processor at predetermined amplitude for a predetermined period of time at a controlled temperature.

Abstract: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.

Abstract: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.

Abstract: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.